Texas House of Representatives · 90th Legislature, Regular Session
Official title: Relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.
Members who authored, joint-authored, or co-sponsored this bill.
SourceLegiScan (CC BY 4.0)90R
Current law in Section 1369.654 of the Insurance Code says a health benefit plan company that covers prescription drugs may not require a patient to get prior authorization (advance approval from the insurer before it will cover a drug) more than once a year for drugs that treat an autoimmune disease, hemophilia, or Von Willebrand disease. This bill adds neurodegenerative diseases to that list, so the once-a-year limit would also apply to drugs prescribed for those conditions. The bill also changes the title of Subchapter N, Chapter 1369, to mention neurodegenerative diseases. The bill adds one exception: a plan company may require prior authorization when a patient is prescribed a new drug to treat a neurodegenerative disease. The bill does not define "neurodegenerative disease" or say what counts as a "new" drug in the text provided. The changes apply only to health benefit plans delivered, issued, or renewed on or after January 1, 2028, and plans delivered, issued, or renewed before that date stay under the earlier law. The bill takes effect September 1, 2027. Its cost is not stated in the bill text.
Read the full text below for the definitive meaning.
Each version links to the authoritative document on capitol.texas.gov.
90R3268 DNC-D By: Jones of Dallas H.B. No. 642 A BILL TO BE ENTITLED AN ACT relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. The heading to Subchapter N, Chapter 1369, Insurance Code, is amended to read as follows: SUBCHAPTER N. COVERAGE OF PRESCRIPTION DRUGS FOR AUTOIMMUNE AND
NEURODEGENERATIVE DISEASES AND CERTAIN BLOOD DISORDERS SECTION 2. Section 1369.654, Insurance Code, is amended by amending Subsection (a) and adding Subsection (c) to read as follows: (a) A health benefit plan issuer that provides prescription drug benefits may not require an enrollee to receive more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat an autoimmune disease, a neurodegenerative disease, hemophilia, or Von Willebrand disease. (c) Notwithstanding Subsection (a), a health benefit plan issuer may require an enrollee who is prescribed a new prescription drug to treat a neurodegenerative disease to obtain a prior authorization for the prescription drug. SECTION 3. The change in law made by this Act applies only to a health benefit plan that is delivered, issued for delivery, or renewed on or after January 1, 2028. A health benefit plan delivered, issued for delivery, or renewed before January 1, 2028, is governed by the law as it existed immediately before the effective date of this Act, and that law is continued in effect for that purpose. SECTION 4. This Act takes effect September 1, 2027.
Statewide figures for the subjects tagged on this bill, to explore on the Data map. They describe Texas — not this bill or its effects.
SourceU.S. Census Bureau (ACS) & CDC PLACESstatewide Data layer
Each subject links to other 90R bills tagged the same way.
SourceLegiScan (CC BY 4.0)subject tags
SourceTexas Legislative Council (capitol.texas.gov)90R
No recorded roll-call votes on this bill.
SourceLegiScan (CC BY 4.0)90R
No fiscal notes or analyses recorded for this bill.
SourceLegiScan (CC BY 4.0)official fiscal notes & analyses (TLC)
Perch never collects comments itself — it points you to the Legislature's own hearing schedule and official public-comment channels (ADR-0007).
Official hearings & comment (capitol.texas.gov) →SourceTexas Legislative Council (capitol.texas.gov)official bill text (capitol.texas.gov)